ARS Pharmaceuticals, Inc. (SPRY)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ARS Pharmaceuticals, Inc. (“ARS” or “the Company”) (NASDAQ: SPRY). Investors who purchased ARS securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether ARS has violated federal securities laws.
ARS Investigation Details
On June 24, 2026, the Company disclosed that Neffy®, its flagship epinephrine nasal spray, received zero new commercial formulary additions or payer-coverage decisions in the July 1, 2026 review cycle. This news followed optimistic statements by the Company’s CEO and other executives, who anticipated “being on formulary for CVS Caremark, Anthem, Aetna and others by July 1 in time for the summer peak prescribing season.”
Following this news, ARS shares dropped sharply in after-hours trading.
What’s Next for ARS Investors?
If you are aware of any facts relating to this investigation or purchased ARS securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
No Cost to ARS Investors
We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC For ARS Securities Investigation?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace,” said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]
Attorney advertising.
Prior results do not guarantee similar outcomes.